II-01 Khaled Abduljalil
Impact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction
Wednesday 15:35-17:00 |
II-02 Tariq Abdulla
Using Simcyp Designer to extend a PBPK-QSP Model of Warfarin to Target Binding
Wednesday 15:35-17:00 |
II-14 Mattia Berton
Physiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine
Wednesday 15:35-17:00 |
II-15 Sara Bettonte
Onset and disappearance of induction on CYP3A4 and UGT1A1 substrates using PBPK modelling
Wednesday 15:35-17:00 |
II-21 THAM THI BUI
Development of a physiological-based pharmacokinetic model for sacubitril and its metabolite
Wednesday 15:35-17:00 |
II-23 Elisa Calvier
PBPK modelling of the DDI between a Drug X and gemfibrozil
Wednesday 15:35-17:00 |
II-27 Marylore Chenel
Physiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis
Wednesday 15:35-17:00 |
II-29 Brian Cicali
Long-acting formulation drug-drug interactions: evaluating the importance of timing using a subcutaneous levonorgestrel PBPK example
Wednesday 15:35-17:00 |
II-33 Marina Cuquerella Gilabert
Title: Development of a Compartmental Advanced Physiologically based Dissolution, Absorption and Transit (CA-PhysDAT) model in PhysPK
Wednesday 15:35-17:00 |
II-37 Neel Deferm
Development of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer
Wednesday 15:35-17:00 |
II-38 Cleo Demeester
Implementation of Oral Drug Absorption in Older Adults in the Physiologically Based Pharmacokinetic (PBPK) Modelling Platforms
Wednesday 15:35-17:00 |
II-39 Abdallah Derbalah
Characterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model
Wednesday 15:35-17:00 |
II-41 Ilse Dubbelboer
Lactation related milk volume changes: implementation in a PBPK cow model for oxytetracycline
Wednesday 15:35-17:00 |
II-57 Berfin Gülave
P-glycoprotein mediated drug-drug interaction at the blood-brain barrier on morphine brain distribution
Wednesday 15:35-17:00 |
II-58 Andrea Guzmán
Individualized Tacrolimus dosing in pediatric kidney transplantation: identification of new genomic, proteomic and metabolomic biomarkers and PhysPK® development of PBPK-based predictive models, simulations and applications in different phamacogenomic subpopulations.
Wednesday 15:35-17:00 |
II-61 Sara Carolina Henriques
Development of a joint dissolution and pharmacokinetic model of propafenone and its hydroxylated metabolite
Wednesday 15:35-17:00 |
II-65 Manuel Ibarra
Enhancing the predictive accuracy of PBPK models for drug concentrations in tissues: accounting for the impact of relative distribution of blood flow
Wednesday 15:35-17:00 |
II-67 Nattapon Jaisupa
A physiologically-based pharmacokinetic model for prediction of cannabidiol pediatric dose
Wednesday 15:35-17:00 |
II-68 Masoud Jamei
Application of a PBPK Model to Predict the Required Ceftazidime Concentration and Duration in Maternal and Umbilical Plasma Prior to Caesarean Section in Virtual Pregnant Women with Different Renal Function
Wednesday 15:35-17:00 |
III-16 Christos Kaikousidis
In Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data
Thursday 10:15-11:45 |
III-22 Christina Kovar
Physiologically Based Pharmacokinetic Modeling of Dasatinib to Describe Enzyme-Mediated and pH-Dependent Drug–Drug Interaction Scenarios
Thursday 10:15-11:45 |
III-24 Katharina Krollik
Oral absorption modeling of weakly basic drugs – Combining in vitro and in silico models
Thursday 10:15-11:45 |
III-27 Julia Larsson
PK and PBPK modeling approaches to describe the lung and systemic exposure after inhalation of AZD4604
Thursday 10:15-11:45 |
III-30 Maxime Le Merdy
Ocular Exposure Extrapolation Across Multiple Species Using PBPK Modeling and Simulation: Latanoprost Solution Case Study
Thursday 10:15-11:45 |
III-36 Cong Liu
Application of translational physiologically based pharmacokinetic (PBPK) model for elucidating the complex disposition of ADCs: a case study with T-DM1
Thursday 10:15-11:45 |
III-37 Feiyan Liu
Unravelling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal excretion and CYP3A4-mediated metabolism
Thursday 10:15-11:45 |
III-40 Helena Loer
Physiologically Based Pharmacokinetic Modeling of Imatinib and Its Main Metabolite for Drug–Drug Interaction Predictions
Thursday 10:15-11:45 |
III-42 Orphélie Lootens
Building a physiologically-based pharmacokinetic model for a carcinogenic food contaminant aflatoxin B1
Thursday 10:15-11:45 |
III-54 Thi Lien Ngo
Development of a Physiological-Based Pharmacokinetic Model for Ritonavir: Unraveling its Triphasic Effects as CYP3A Inhibitor, CYP3A Inducer, and Pgp Inhibitor.
Thursday 10:15-11:45 |
III-57 Jessica Ou
Development of a physiologically-based pharmacokinetic model to understand and predict the disposition of gallium-68 radiolabeled-dendrimers in vivo
Thursday 10:15-11:45 |
III-59 Sara Peribanez
A physiologically-based pharmacokinetic model for V937, a novel oncolytic virus, in mice
Thursday 10:15-11:45 |
III-61 Luna Prieto Garcia
An Integrated PBPK-Quantitative Systems Pharmacology Model for Statins to Assess the Variability and Implications of Transporter-Mediated Distribution
Thursday 10:15-11:45 |
III-63 Federico Reali
A minimal PBPK mice model to support the preclinical development of drugs against tuberculosis.
Thursday 10:15-11:45 |
III-64 Javier Reig-López
Chirality matters: physiologically based pharmacokinetic modelling of ibuprofen enantiomers
Thursday 10:15-11:45 |
III-69 Anuraag Saini
Development of mPBPK model to support translation decision-making for novel bispecific therapeutics
Thursday 10:15-11:45 |
III-70 Ayatallah Saleh
Unravelling the complex inhibition network of voriconazole and its metabolites using a middle-out PBPK approach
Thursday 10:15-11:45 |
III-81 Erik Sjögren
Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework
Thursday 10:15-11:45 |
III-90 Cristian Valiante
PBPK model-based extrapolation from adults to children to predict furosemide oral solution bioavailability
Thursday 10:15-11:45 |
III-94 Tan Zhang
Exploring the impact of obesity on drug clearance using PBPK modelling approaches: influential variables affecting scaling from non-obese to obese subjects for drugs metabolized in the liver
Thursday 10:15-11:45 |
